Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib

被引：1

作者：

Mueller, Martin C. ^{[1
]}

Baccarani, Michele ^{[2
]}

Deininger, Michael W. ^{[3
]}

Guilhot, Francois ^{[4
]}

Hochhaus, Andreas ^{[5
]}

Hughes, Timothy P. ^{[6
]}

Shah, Neil P. ^{[7
]}

Talpaz, Moshe ^{[8
]}

Lustgarten, Stephanie ^{[9
]}

Rivera, Victor M. ^{[9
]}

Clackson, Tim ^{[9
]}

Haluska, Frank G. ^{[9
]}

Cortes, Jorge E. ^{[10
]}

机构：

[1] Univ Med Mannheim, Mannheim, Germany

[2] S Orsola Malpighi Univ Hosp, Bologna, Italy

[3] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA

[4] Univ Hosp, Poitiers, France

[5] Jena Univ Hosp, Jena, Germany

[6] Inst Med & Vet Sci, Adelaide, SA 5000, Australia

[7] Univ Calif San Francisco, San Francisco, CA 94143 USA

[8] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[9] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.518.518

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)
Le Coutre, Philipp D.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
Dipersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Yanase, Kumiko
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
Kantarjian, Hagop M.
Cortes, Jorge E.
BLOOD, 2013, 122 (21)
[2] Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
Mueller, Martin C.
Cortes, Jorge
Chuah, Charles
DeAngelo, Daniel J.
Deininger, Michael
Guilhot, Francois
Hughes, Timothy
Nicolini, Franck E.
Pinilla-Ibarz, Javier
Rea, Delphine
Rosti, Gianantonio
Shah, Neil P.
Talpaz, Moshe
Lu, Vickie
Padukkavidana, Thihan
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S336 - S337
[3] RESPONSES AT EARLY LANDMARK TIME POINTS ARE ASSOCIATED WITH OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS (PTS) TREATED WITH PONATINIB
Mueller, M.
Baccarani, M.
Deininger, M. W.
Guilhot, F.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Talpaz, M.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Cortes, J. E.
HAEMATOLOGICA, 2015, 100 : 65 - 65
[4] 5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
Cortes, J. E.
Kantarjian, H. M.
Pinilla-Ibarz, J.
le Coutre, P. D.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
Baccarani, M.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Lustgarten, S.
Santillana, S.
Rivera, V. M.
Clackson, T.
Mueller, M. C.
HAEMATOLOGICA, 2017, 102 : 236 - 237
[5] Is Quality of Life (QOL) Predictive for Clinical Response in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients Treated with Dasatinib?
Ionova, Tatiana
Bulieva, Natalia
Golenkov, Anatoly
Gritsenko, Taras
Kozlova, Lilia
Kuchma, Galina
Lomaia, Elza
Machulaytene, Elena
Nikitina, Tatiana
Novitskaya, Natalia
Usacheva, Elena
Shneider, Tatiana
Trifonova, Elena
Vinogradova, Olga
Zinkovskaya, Anna
BLOOD, 2017, 130
[6] Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).
Muller, Martin C.
Baccarani, Michele
Deininger, Michael W. N.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Talpaz, Moshe
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Timothy Piers
Haluska, Frank G.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
Lipton, Jeffrey H.
Chuah, Charles
Guerci-Bresler, Agnes
Rosti, Gianantonio
Simpson, David
Assouline, Sarit
Etienne, Gabriel
Nicolini, Franck E.
Le Coutre, Philipp
Clark, Richard
Stenke, Leif
Andorsky, David
Oehler, Vivian
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Haluska, Frank G.
Baccarani, Michele
Cortes, Jorge E.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Kantarjian, Hagop M.
Shah, Neil P.
Talpaz, Moshe
Deininger, Michael W.
BLOOD, 2014, 124 (21)
[8] Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Kantarjian, Hagop M.
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
BLOOD, 2013, 122 (21)
[9] LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS
Mueller, M.
Baccarani, M.
Deininger, M. W.
Guilhot, F.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Talpaz, M.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Cortes, J. E.
HAEMATOLOGICA, 2016, 101 : 239 - 239
[10] COST-EFFECTIVENESS ANALYSIS OF PONATINIB IN THE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SWEDEN
Iannazzo, S.
McGarry, L.
Chiroli, S.
VALUE IN HEALTH, 2015, 18 (07) : A668 - A668

← 1 2 3 4 5 →